Tuesday, April 16, 2024 3:33:34 PM
Is this the calm before the storm?
We all seem to be set in our positions, waiting to see what the UK does, waiting to see the status of the EDEN unit, waiting to see when the company announces an Annual Meeting, etc.
Nothing we say can change any of this, but we all have our opinions of what's happening, but the facts must come from the regulators, and the company.
I'll restate my belief that the UK will approve on time, but I'll admit not knowing if on time to them now means 120 days, or if 150 days remains the target for this decision on their part. Early next week we're at the 120 day point, if nothing has been heard from the UK, I'll assume that they're looking at one month later. A decision can be made on any day, the company should be notified, then I believe they would have up to 4 days to notify investors based on SEC regulations. To me, if a positive decision cannot be announced by the open on Wednesday, I'd prefer it be held till at least the weekend, and rolled out in a way that maximizes attention to it. Other than an Annual Meeting or Expert Theater presentation at ASCO I cannot remember when the company has spoken to investors, or the general investment public. I have recently seen other companies get both good and bad trial news or regulatory decisions, in each case a webcast was announced at the same time the news was announced. I would hope that NWBO would have the same respect for investors and hold a webcast shortly after the news, good or bad. As a West Coast investor I prefer such webcasts during the market day, but I recognize that they're often held before the open. On more than one occasion the news was announced roughly one to two hours before the open and the webcast made a half hour to an hour after the announcement, I very much doubt that most investors were aware of it when it was live, but such webcasts should almost immediately be available for replay on the company website.
Speaking of the Experts Theater at ASCO, I would believe that once again the company will present there. What they have to say may largely depend on what does, or doesn't happen between now and then. I don't know if Abstracts were submitted for peer reviewed presentations of any of the other trials at UCLA, or elsewhere, but it's possible. Abstracts are due early February, new data may be added to the actual presentation, but submission must be timely. The Experts Theater isn't considered peer reviewed, but information that's right up to the minute can be presented there. If the company does what it's done in the past at ASCO, they'll have one of the larger exhibitors booth, and they'll have an hour to present at the Experts Theater, which has been webcast in the past.
Gary
We all seem to be set in our positions, waiting to see what the UK does, waiting to see the status of the EDEN unit, waiting to see when the company announces an Annual Meeting, etc.
Nothing we say can change any of this, but we all have our opinions of what's happening, but the facts must come from the regulators, and the company.
I'll restate my belief that the UK will approve on time, but I'll admit not knowing if on time to them now means 120 days, or if 150 days remains the target for this decision on their part. Early next week we're at the 120 day point, if nothing has been heard from the UK, I'll assume that they're looking at one month later. A decision can be made on any day, the company should be notified, then I believe they would have up to 4 days to notify investors based on SEC regulations. To me, if a positive decision cannot be announced by the open on Wednesday, I'd prefer it be held till at least the weekend, and rolled out in a way that maximizes attention to it. Other than an Annual Meeting or Expert Theater presentation at ASCO I cannot remember when the company has spoken to investors, or the general investment public. I have recently seen other companies get both good and bad trial news or regulatory decisions, in each case a webcast was announced at the same time the news was announced. I would hope that NWBO would have the same respect for investors and hold a webcast shortly after the news, good or bad. As a West Coast investor I prefer such webcasts during the market day, but I recognize that they're often held before the open. On more than one occasion the news was announced roughly one to two hours before the open and the webcast made a half hour to an hour after the announcement, I very much doubt that most investors were aware of it when it was live, but such webcasts should almost immediately be available for replay on the company website.
Speaking of the Experts Theater at ASCO, I would believe that once again the company will present there. What they have to say may largely depend on what does, or doesn't happen between now and then. I don't know if Abstracts were submitted for peer reviewed presentations of any of the other trials at UCLA, or elsewhere, but it's possible. Abstracts are due early February, new data may be added to the actual presentation, but submission must be timely. The Experts Theater isn't considered peer reviewed, but information that's right up to the minute can be presented there. If the company does what it's done in the past at ASCO, they'll have one of the larger exhibitors booth, and they'll have an hour to present at the Experts Theater, which has been webcast in the past.
Gary
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
